RGEN (Repligen) Beginning Cash Position: $566.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGEN Repligen Corp RGEN
87 GF Score
Price $148.06
GF Value $176.86
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Beginning Cash Position?

Repligen RGEN +0.63% 87 Beginning Cash Position is $566.0 Mil as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 87/100 and a GF Value™ of $176.86 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Repligen's Beginning Cash Position for the quarter that ended in Mar. 2026 was $566.0 Mil.

Repligen's quarterly Beginning Cash Position increased from Sep. 2025 ($708.9 Mil) to Dec. 2025 ($748.7 Mil) but then declined from Dec. 2025 ($748.7 Mil) to Mar. 2026 ($566.0 Mil).

Repligen's annual Beginning Cash Position increased from Dec. 2023 ($523.5 Mil) to Dec. 2024 ($751.3 Mil) and increased from Dec. 2024 ($751.3 Mil) to Dec. 2025 ($757.4 Mil).

Repligen Beginning Cash Position Related Terms

Repligen Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Repligen's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Beginning Cash Position Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 717.29 603.81 523.46 751.32 757.36

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 757.36 697.23 708.86 748.75 566.02
RGEN
87GF Score
Repligen Corp RGEN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $566.0 Mil mean?
Repligen (RGEN) has a Beginning Cash Position of $566.0 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Repligen and its competitors.
Is Repligen's Beginning Cash Position too high?
Repligen's current Beginning Cash Position is $566.0 Mil. Overall, Repligen has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Beginning Cash Position compare to ATR and AVTR?
Repligen's Beginning Cash Position of $566.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Repligen and its competitors. Repligen's current Beginning Cash Position is $566.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.86, compared to a current price of $148.06 — trading 16.3% below its estimated fair value. The current Beginning Cash Position is $566.0 Mil. Repligen's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Repligen (RGEN), the current Beginning Cash Position is $566.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $148.06 is trading 16.3% below its estimated GF Value™ of $176.86. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Beginning Cash Position: $566.0 Mil
  • GF Value™: $176.86 vs. price of $148.06 (16.3% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
87GF Score

Get the complete analysis for RGEN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$148.06
Price
$176.86
GF Value